Scrutiny Urged For FDA Divisions With High Number Of Delayed Postmarketing Studies
Postmarketing studies are more likely to be delayed in some Center for Drug Evaluation and Research review divisions than others, and one of FDA’s consultants wants the agency to find out why.
You may also be interested in...
While more than half of the post-marketing commitment backlog from 2007 and earlier has been cleared from FDA’s books, but the portion of “delayed” studies has remained consistent.
A more than two-fold increase in the number of concluded study requirements and commitments in fiscal 2009 appears largely attributable to a consulting firm's clean-up of FDA's postmarketing obligations database.
CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.